Human Phenotyping and Immune Cell

核心B的功能是为每个项目提供人类和免疫细胞表型，这将是将机械发现转化为人类模型的关键。 免疫细胞变异对人类动脉粥样硬化的影响代表了人们对动脉粥样硬化形成和可能的动脉粥样硬化保护的一个普遍了解的领域。人类表型和免疫细胞核心(核心B)的目标是提供必要的资源，将小鼠模型中明确定义的动脉粥样硬化的新免疫机制转化为人类模型。具体地说，我们将提供明确定义的2型糖尿病患者动脉粥样硬化负担和风险的表型， 使用流式细胞术进行人类免疫细胞的基因分型分析和表型描述。核心B将与三个项目中的每个项目合作，使用Framingham风险评分和颈动脉内膜-中层厚度(项目1-3)为患有和不患有2型糖尿病的患者提供明确的动脉粥样硬化负担和风险的表型；传统动脉粥样硬化危险因素的血清和血浆测量(项目 项目1-3)；与动脉粥样硬化机制有关的单核苷酸多态基因分型(项目3)；免疫细胞的分离和流式细胞仪分析(项目1-3)；收集和运送血清和血浆供个别项目分析(项目1-3)。

The function of Core B is to provide human and immune cell phenotyping for each project that will be critical to the translation of mechanistic findings into the human model. The effects of immune cell variations on atherosclerosis in humans represents a poody understood area of atherogenesis and possible atheroprotection. The goal of the Human Phenotyping and Immune Cell Core (Core B) is to provide the resources necessary for translation of novel immune mechanisms of atherosclerosis that are well defined in murine models into the human model. Specifically, we will provide well-defined phenotypes of atherosclerosis burden and risk in patients with and without type 2 diabetes, genotyping analysis, and phenotypic descriptions of immune cells in humans using flow cytometry. Core B will work with each of the three projects to provide in patients, with and without Type 2 diabetes, well-defined phenotypes of atherosclerosis burden and risk using the Framingham risk Score and carotid intima-media thickness (projects 1-3); serum and plasma measurement of traditional atherosclerotic risk factors (projects 1-3); genotyping of single nucleotide polymorphisms related to atherosclerotic mechanisms (project 3); isolation and FACS analysis of immune cells (projects 1,3); and collection and shipping of serum and plasma for analysis by individual projects (projects 1-3).